8-KMaterial AgreementsFinancial EventsExhibits & Filings

AGILENT TECHNOLOGIES, INC. 8-K Report, Material Agreement (Sep 9, 2024)

Filed September 9, 2024For Securities:A

Summary

Agilent Technologies, Inc. has successfully closed a public offering of $1.2 billion in aggregate principal amount of senior notes. This issuance comprises $600 million of 4.200% Senior Notes due 2027 and $600 million of 4.750% Senior Notes due 2034. The proceeds from this offering will be used to fund the company's operations and strategic initiatives. The new notes are unsecured and rank equally with Agilent's existing senior unsecured indebtedness. The terms include provisions for redemption by the company under specific conditions, including a 'Par Call Date' and a 'Change of Control Repurchase Event.' Notably, the 2027 Notes are subject to a special mandatory redemption at a higher principal amount (101%) if the 'BioVectra Acquisition' is not completed by a specified date or if Agilent decides not to proceed with it. This indicates the acquisition is a significant factor tied to the financing.

Key Highlights

  • 1Agilent Technologies closed a $1.2 billion senior notes offering.
  • 2The offering includes $600 million in 4.200% Senior Notes due 2027 and $600 million in 4.750% Senior Notes due 2034.
  • 3The notes are unsecured and rank equally with other senior unsecured debt.
  • 4The 2027 Notes include a special mandatory redemption clause tied to the BioVectra Acquisition, requiring repurchase at 101% of principal if the acquisition doesn't close or is abandoned.
  • 5The 2034 Notes do not have the same mandatory redemption provision related to the BioVectra Acquisition.
  • 6Standard covenants limiting liens, sale-leaseback transactions, and asset sales are included.
  • 7Customary events of default are outlined, including payment failures, covenant breaches, and bankruptcy.

Frequently Asked Questions

The filing does not explicitly state the use of proceeds for this $1.2 billion debt offering. Typically, companies issue debt for general corporate purposes, which can include funding operations, capital expenditures, acquisitions, or refinancing existing debt. Investors should look for further disclosures in subsequent SEC filings or earnings calls for specific details on fund utilization.

The 2027 Notes are subject to a special mandatory redemption at a premium (101% of principal plus accrued interest) if the BioVectra Acquisition is not consummated by a specified date or if Agilent decides not to proceed with it. This suggests that the successful completion of the BioVectra Acquisition is crucial for Agilent to avoid an earlier, more expensive redemption of the 2027 Notes.

Agilent issued $600 million of 4.200% Senior Notes due September 9, 2027, and $600 million of 4.750% Senior Notes due September 9, 2034. Interest on both series is payable semi-annually.

No, the 4.200% Senior Notes due 2027 and the 4.750% Senior Notes due 2034 are unsecured. They rank equally in right of payment with Agilent's other senior unsecured indebtedness.